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Epsilon-aminocaproic Acid for Treatment of Fibrinolysis during 
Liver Transplantation 
Yoogoo Kang, M.D.,· Jessica H. Lewis, M.D., t Ashok Navalgund, M.D., • Michael W. Russell, M.D.,· 
Franklin A. Bontempo, M.D.,l Lawrence S. Niren, M.D.,· Thomas E. StaS M.D., Ph.D.§ 
In 97 adult patients receiving liver transplants, the coagulation 
system was monitored by thrombelastography and by coagulation 
profile including PT; aPTT; platelet count; level of factors I, II, V, 
VII, VIII, IX, X, XI, and XII; fibrin degradation products; ethanol 
gel test; protamine gel test; and euglobulin lysis time. Preoperatively, 
fibrinolysis defined as a whole blood clot lysis index of less than 
80% was present in 29 patients (29.9%), and a euglobulin lysis time 
of less than 1 h was present in 13 patients. Fibrinolysis increased 
progressively during surgery in 80 patients (82.5%) and was most 
severe on reperfusion of the graft liver in 33 patients (34%). When 
whole blood clot lysis (F < 180 min) was observed during reperfusion 
of the graft liver, blex>d coagulability was tested by thrombelastog-
raphy using both a blood sample treated in vitro "ith t-aminocaproic 
acid (0.09%) and an untreated sample. Blood treated with ... amino-
caproic acid showed improved coagulation without fibrinolytic ac-
tivity in all 74 tests. When whole blood clot lysis time was less than 
120 min, generalized oozing occurred, and the effectiveness of t-
aminocaproic acid was demonstrated in vilro during the pre-anhe-
patic and post·anhepatic stages, t-aminocaproic acid (1 g, single in-
travenous dose) was administered. In all 20 patients treated with Eo 
aminocaproic acid, fibrinolytic activity disappeared; whole blood 
clot lysis was not seen on thrombelastography during a 5-h obser-
vation period, and whole blood clot lysis index improved from 28.5 
± 29.5% to 94.8 ± 7.4% (mean ± SD, P < 0.001). None of the treated 
patients had hemorrhagic or thrombotic complications. In patients 
undergoing liver transplantation, the judicious use of a small dose 
of t-aminocaproic acid, when its efficacy was confirmed in vitro, ef-
fectively treated the severe fibrinolysis without clinical thrombotic 
complications. (Key words: Blood: coagulation; fibrinolysis. Liver: 
transplantation. Measurement techniques: thrombelastography. 
Pharmacology: ... aminocaproic acid.) 
ORTHOTOPIC LIVER TRANSPLANTATION is frequently 
associated with surgical bleeding that requires massive 
blood transfusion. 1 The surgical bleeding is compounded 
by preexisting coagulopathy, dilutional coagulopathy, fi-
brinolysis, and, possibly, disseminated intravascular co-
agulation.2 In a recent series of patients undergoing liver 
transplantation, the degree of coagulopathy and volume 
of transfusion decreased with the introduction of replace-
ment therapy guided by the frequent thrombelastographic 
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monitoring of the coagulation system and the use of hep-
arin-coated veno-venous bypassK~·4 However, active fibri-
nolysis, manifest as generalized oozing from a previously 
dry surgical field and unresponsive to replacement ther-
apy, has been a major difficulty in the intraoperative man-
agement of liver transplantation. 
Since the early experience in hepatic transplantation. 
activation of the fibrinolytic system has been recognized,5.6 
and, although antifibrinolytic treatment appears benefi-
cial, it has been used only sporadically. Von Kaulla et al.. 
on the basis of postoperative thrombotic complications in 
patients with hepatic neoplasms, suggested that admin-
istration of E-aminocaproic acid (EACA) might be harmful 
in transient fibrinolysis,6 whereas Flute et al. suggested a 
possible beneficial role of EACA in patients receiving liver 
transplants.? Thus far, anti fibrinolytic therapy has been 
empirical; its indications have been ill defined, monitoring 
of fibrinolysis has been inadequate, and, usually, a large 
dose of EACA has been used in cases of uncontrolled 
bleeding. We designed the present study to investigate 
the significance of fibrinolysis. to evaluate the clinical ef-
fectiveness of EACA, and to identify a clinically effective 
dose of EACA in patients receiving liver transplants. 
Methods 
After the study protocol was approved by the Institu-
tional Review Board for Biomedical Research at the Uni-
versity of Pittsburgh, adult patients undergoing liver 
transplantation between October 1983 and January 1985 
were observed prospectively. Two 8.5-French in-dwelling 
catheters were inserted for volume infusion, one in the 
antecubital vein, and another in the external or intema1 
jugular vein. In addition, a flow-directed pulmonary ar-
tery catheter with on-line oximetry was inserted via the 
right internal jugular vein, and two indwelling intraar-
terial catheters were placed in the radial arteries, one for 
pressure monitoring, and one for blood sampling and 
back-up pressure monitoring. A heparin-coated vena-ve-
nous bypass system (Biomedicus Inc., Minnetonka, MN) 
was used in all patients during the anhepatic stage. A 
rapid-infusion systemS was used to replace lost blood vol-
ume with a fixed fluid composition of packed red blood 
cells (RBC), fresh frozen plasma (FFP), and electrolyte 
solution (Plasma-Iyte A-, Travenol Laboratories fnc~I 
Deerfield, IL 60015) in a ratio of 300:200:250 mi. FFP 
was added to prevent dilutional coagulopathy. The blood 
-----_.-----_ ... _------
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mixture yielded levels of: fibrinogen, 130 mg%; factor 
II, 0.59 U/ml; factor V, 0.21 Vlml; and factor VIII, 
0.57 U/m!. Electrolyte solution was added to decrease 
hematocrit to 27 ± 2%, to reduce the loss of RBC, and to 
improve circulatory rheology. Transfusion of additional 
blood components was guided by variables measured by 
thrombelastography (TEG): 2 units of fresh frozen plasma 
were given when reaction time was longer than 15 min, 
10 units of platelets when maximum amplitude was less 
than 40 mm, and 6 units of cryoprecipitate when clot 
formation rate was persistently less than 40°. 
TEG is shown schematically in figure 1. The device 
consists of a highly polished stainless steel cup that contains 
whole blood (0.36 ml) and a pin freely suspended by a 
torsion wire. The temperature of the cup is kept at 37° 
C. It oscillates on its vertical axis of 4.45 ° every 9 s. Ini-
tially. blood injected into the cup remains fluid, and the 
oscillation of the cup is not transmitted to the pin. As 
fibrin strands form between the surfaces of the cup and 
the pin, the shear elasticity of fibrin strands increases, and 
the motion of the cup is coupled to the pin. The motion 
of the pin, in tum, is transmitted to the torsion wire and 
recorded on thermal paper. Therefore, TEG monitors 
the entire process of coagulation, including the initial fluid 
state without fibrin strands, the gradual increase in 
strength of fibrin strands (coagulation), and the resolution 
of fibrin strands (fibrinolysis). The variables measured by 
TEG are: reaction time (r [min]), coagulation time (r + k 
[minD, clot formation rate (a [0]), maximum amplitude 
(MA [mm ]), amplitude 60 min after maximum amplitude 
E~[mmzFI whole blood clot lysis index (WBCLI, Awl 
MA· 100 [% D, and whole blood clot lysis time (F [min]) 
(fig. 2). 
The surgical procedure is divided into three stages, 
according to distinctive anatomic and physiologic altera-
tions at each stage. The preanhepatic stage (stage 1), be-
gins at induction of anesthesia and .ends a,t !!.epatectomy-
The anhepatic stage (stage 2) is the period between hep-
atectomy and reperfusion of the graft liver by portal ve-
nous blood. The postanhepatic stage (stage 3) lasts from 
reperfusion of the graft liver to the end of surgery. 
EVALUATION OF FIBRINOLYSIS 
Blood samples (15 ml each) were obtained from an un-
heparinized indwelling arterial catheter for coagulation 
monitoring at the following times: before induction of 
anesthesia; 30 min into surgery; thereafter every 2 h or 
after infusion of every 6 I of fluid volume; 5 min before 
removing the liver; 5 min into the an hepatic stage; 30 
min into the anhepatic stage; 5 min before reperfusion 
of the graft liver; 5 min after reperfusion of the graft 
liver; SO min after reperfusion of the graft liver; and 
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FIG. 1. Schematic diagram of thrombelastography. 
The blood samples were tested by TEG and coagulation 
profile. Whole blood (0.36 ml) was used for TEG tests,9 
and recordings began 4 min after blood sampling. Mea-
sured coagulation profile variables included platelet count; 
prothrombin time (PT); activated partial thromboplastin 
time (aPTT); thrombin time (TT); reptilase time (RT); 
level of factors I, II, V, VII, VIII, IX, X, XI, and XII; 
fibrin degradation products (FDP); ethanol gel test; prot-
amine gel test; and euglobulin lysis time (EL T).lO-12 Fi-
brinolysis was defined to be present when complete whole 
blood clot lysis was observed within 3 h or when whole 
blood clot lysis index (WBCLI) was less than 80%. 
EVALUATION OF EACA IN VrrRO -
When blood clot lysis time (F) _was less than 180 min 
or 5 min after reperfusion of the graft liver, two blood 
4 min F ---~Fj 
FIG. 2. Variables measured by thrombelastography and their normal 
values: r = reaction time (min); r + ... - coagulation time (min); a 
= clot formation rate (0); MA - maximum amplitude (mm); "- -
amplitude 60 min after maximum amplitude (mm); F = whole blood 
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TABLE I. Thrombelastographic Variables and Coagulation Profile 
in the mreo~rative Period and in the Most ~ctKive ci~rinolytic 
Stage in SO Patients Who Showed FlbnnolyslS 
Normal 
s~riable V.I_ Preop<ntM Period Fibrinolytic Stage 
Reaction time 
(min) 6-S 9.S8± 7.66 10.71±12.1 
Coagulation time 
16.7 ± 12.S 14.1 ± 7.0 (min) 10-12 
Maximum 
amplitude (mm) 50-70 44.8 ± 14.S S2.6 ± 15.6* 
Clot formation rate 
(0) >50 42.1 ± 16.4 S6.6 ± 18.S* 
Whole blood clot 
lysis index (%) >80 SO.9 ± 17.4 2S.9 ±27.7* 
Prothrombin time 
(5) II-IS 14.7 ± S.7 15.5 ± S.4* 
Activated paniaJ 
thromboplastin 
time (5) 26-S4 46.5 ± 21.8 60.2 ±S2.5* 
Thrombin time (5) IS-IS 26.8 ± 11.6 29.7 ± 1:5.1 
Platelet count 
(IOOO/mm') 150-450 122.4 ± 128.8 92.8 ± 58.7* 
Fibrinogen Em~F 150-450 198.0 ± 10S.S 129.S ±66.0* 
Factor II (U/m!) 0.5-1.5 0.5S± 0.25 0.50± 0.17* 
Factor V (U/mI) 0.5-1.5 0.47± 0.29 O.SO± 0.15* 
Factor VII (U/ml) 0.5-1.5 0.47± 0.S2 0.S8± 0.21· 
Factor VIII 
(U/ml) 0.5-1.5 1.79± 0.87 1.22± 0.70· 
Values are means ± SD. 
• P < 0.05 compared with preoperative values. 
samples were tested by TEG; one sample (0.33 ml) was 
treated with 0.03 ml of EACA (1 % solution). and the 
other (0.36 ml) was untreated blood. The TEG variables 
measured in EACA-treated blood and in untreated blood 
were compared. 
Wilcoxon test for paired data, and analysis of variance of 
repeated measures. and specific differences were assessed 
with the Student-Newman-Keuls test. P < 0.05 was con-
sidered statistically significant. 
Results 
EVALUATION OF FIBRINOLYTIC ACTIVITY 
Seventy-nine patients received 97 liver transplants 
during the study period; 18 operations were retransplan-
tations. On 82 occasions. a complete preoperative coag-
ulation profile was available: average PT was IS.0 ± 3.9 
s; aPTT. 46.4 ± 23.4 s; TT. 26.8 ± 11.4 s; RT. 24.6 
± 7.6 s; platelet count. 133.800 ± 142.700/mm'. All co-
agulation factors except fibrinogen (199.S ± 115.4 mg%) 
and factor VIIl (1.78 ± 0.81 V/ml) were 30-60% of 
normal. Preoperative TEG values were available in a1l97 
patients; they showed prolonged reaction time (r. 10.2 
± 7.7 min) and coagulation time (r + k. 17.8 ± 13.S min). 
decreased maximum amplitude (MA. 44.6 ± 14.S mm). 
and decreased clot formation rate (a. 40.9 ± 17.0°). Pre-
operative fibrinolysis was demonstrated by TEG as a whole 
blood clot lysis index (WBCLI) of less than 80% in 29 
patients (30.S%) and complete whole blood clot lysis 
within 3 h in 4 patients. In 13 of 84 patients (IS.S%). 
ELT was 1 h or less preoperatively. 
Intraoperatively. 17 patients (17.5%) showed no sign 
of fibrinolysis (group 1). while 80 patients (82.5%) showed 
signs of fibrinolysis (WBCLI < 80% or F < 180 min) in 
at least one blood sample during the surgical procedure 
(group 2). The pre- and intraoperative coagulation profiles 
of patients in group 1 were not different from those in 
CLINICAL ApPLICATION OF EACA group 2 (P = 0.20). In group 2. fibrinolysis was most 
. .... severe during the preanhepatic stage in 21 patients 
When severe fibrinolysis (F < 120 min) and generalized (26.2%). during the anhepatic stage in 19 patients (23.8%). 
_ oozing occurred during s.urgery. a.n.dfibJin.oly'si;s ~~ preK"IKI~KF~n~d~ring the postanhepatic stage in 40 patients (50%). .... 
vented in vitro in EACA-treated blood. as evidenced by"' Fibrinolysis was most severe immediately afterreperfusion 
an increase in whole blood clot lysis time (F). a single 1- of the graft liver in 33 patients. The duration of fibri-
g dose of EACA was administered intravenously to the nolysis (WBCLI < 80%) was measured from its appear-
patient. However. when active fibrinolysis occurred near ance to its disappearance on the TEG recording. Mean 
the anhepatic stage (from 30 min before removal of the duration was 216 ± 136 min; duration was less than 4 h 
native liver to the completion of the hepatic arterial ana5- in 44 patients and 4-8 h in 36 patients. No patient dem-
tomosis after reperfusion of the graft liver) EACA was onstrated fibrinolysis at the end of surgery. In table 1, 
not given, to avoid possible clot formation jn . the vena- the coagulation profile and TEG values in the most active 
venous bypass circuit. TEG and coagulation profile vari- fibrinolytic stage (defined by the minimum WBCLI) for 
abIes were observed to assess the clinical effectiveness of group 2 patients are compared with preoperative values. 
the anti fibrinolytic therapy. To evaluate the possible mi- The most significant thrombelastographic changes were 
crocirculatory thrombotic effects ofEACA, postoperative a decrease in MA from 44.8 ± 14.3 to 32.6 ± 15.6 mm. 
renal function was assessed by measuring blood urea ni- in clot formation rate (a) from 42.1 ± 16.4 to 36.6 
trogen and serum creatinine levels for 7 postoperative ± 18.S·, and, in WBCLI, from 80.9 ± 17.4 to 23.9 
days. ± 27.7%. Platelet count and all coagulation factor levels 
All measured variables are presented as mean ± SO. decreased. The frequency distribution of whole blood dot 
Data were analyzed by linear regression, nonparametric lysis time, ELT. FOP, and fibrin monomers is shown in 
\. ' .. 
_L _______ .. _. ___ _ 
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qK~Bib 2. Intraoperati\'e Changes in Whole Blood Clot Lysis :ri,:"e. 
Euglobulin Lysis Time. Fibrin Degradation Products. and F.bnn 
Monomers in 68 Patients Who Showed Fibrinolysis 
Number or Patienu 
Preoperative Fibrinolytic 
\'ariabk Period SlOge 
Whole blood clot lysis time 
0-60 min I ~S 
61-120 min 0 25 
121-ISO min 3 S 
> ISO min 64 4 
Euglobulin lysis time 
0-60 min IS 49 
61-120 min 7 4 
>120 min 4S 15 
Fibrin degradation products 
4S o JLg/ml 55 
10-40 !,glml 5 7 
>40 !'g/ml S IS 
Fibrin monomers 
0 56 24 
+ 11 P~ 
++ 1 10 
+++ 0 1 
Whole blood clot lysis time and euglobulin lysis time decreased. and 
level of fibrin monomers increased. during the fibrinolytic stage. 
table 2. Whole blood clot lysis time (F) was less than 120 
min in one patient preoperatively and in 61 patients at 
the most severe fibrinolytic stage (P < 0.05). The changes 
in EL T were similar. The number of patients who showed 
positive soluble fibrin monomers increased during the 
most severe fibrinolytic stage. but the increase in FDP 
was not significant. In group 2 patients. fibrinolysis mea-
sured as EL T did not correlate with whole blood clot lysis 
time (F) or whole blood clot lysis index (fig. 3). 
Ev ALVA TION OF EACA IN VITRO 
When fibrinolysis (F < 180 min) was observed and, 5 
min after reperfusion of the 'graft li:;e~;;th~:qbEf~aiuei D~KD 
in untreated blood were compared with those in EACA-
treated blood (n = 74) (table 3. fig. 4). In treated blood, 
all TEG values improved: WBCLI increased from' 48.9 
± 42.2% to 93.6 ± 16.9%. and whole blood clot lysis did 
not occur during the 5-h observation period in all 74 cases. 
CLINICAL ApPLICATION OF EACA 
EACA (1 g) was administered intravenously to 20 pa-
tients who had oozing from a previously dry surgical field 
and severe fibrinolysis (F < 120 min) that was reversed 
by EACA in vitro. EACA was given during the pre-an-
hepatic stage in five patients and after reperfusion of the 
graft liver in 15 patients. Preoperative coagulation profile 
and TEG values in patients given EACA were similar to 
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FIG. 3. Relation between whole blood clot lysis time (F) and eu-
globulin lysis time (EL T) in patients who demonstrated fibrinolysis. 
The correlation was poor (r = 0.29). 
profile variables measured before and 10 min after the 
administration of EACA are shown in tables 4 and 5 and 
figure 4. The improvement in coagulability is shown by 
increases in MA and WBCLl and whole blood clot lysis 
time (F) longer than 5 h in all patients. But EACA did 
not improve the coagulation profile significantly except 
for a moderate increase in EL T. In all patients given 
EACA, oozing from the surgical field stopped immedi-
ately. and whole blood clot lysis did not recur. 
The clinical course of all patients was observed for 
thrombotic complications. Four patients suffered throm-
TABLE 5. Thrombelastographic Variables in Untreated Blood and 
in Blood Treated with f-aminocaproic Acid (n = 74 Tests) 
Normal Untrealed IIlood Trwed 
Variable V.lua IIlood with EACA 
Reaction time 
(min) 6-S 9.6± 5.4 S.I ± 4.2· 
Coagulation time 
(min) 10-12 24.S± IS.O 19.2± S.2· 
Maximum 
amplitude (mm) 50-70 33.0 ± 14.9 40.3 ± 15.4· 
Clot fonnation rate 
(0) >50 30.7 ± 16.7 S6.4±17.1· 
Whole blood clot 
lysis index (%) >SO 48.9±42.2 93.6± 16.9-
Whole blood clot 
lysis time (min) >ISO 62.6± 38.S >ISOt 
Values are mean ± SD. 
• P < 0.05 compared with corresponding values in untreated blood. 
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120 mln in surgery -
The anhepat lC stace 
5 mln after reperf" •. on 
JUntreated blood 
} Blood treated wi th 
[ACA (0.091) 
-[ACA (1g). IV--+ 
30 min after reperfuslon 
End of surgery 
o 30 60 90 120 180 min 
FIG. 4. Thrombelastographic patterns in a patient undergoing liver 
transplantation. t-aminocaproic acid (EACA. I g) was administered 
intravenously when severe fibrinolysis was observed on thrombelas-
tography. generalized oozing occurred in a previously dry surgical 
field and EACA treated fibrinolysis in vitro. 
botic or hemorrhagic complications intra- or postopera-
tively: two pulmonary emboli, one hepatic arterial throm-
bosis of the grafted liver, and one subarachnoidal hem-
orrhage. None of these patients had received EACA. 
Postoperative renal function measured by blood urea ni-
trogen and serum creatiniJ)(: levels was similar in the two 
groups for 7 days. 
TABLE 4. Thrombelastographic Variables and Coagulation Profile in 
Patients who Received t-aIIIinocaproic Acid (EACA. I g) 
Variable Before EACA 10 Min Alin EACA 
Reaction time (min) 11.1 ± II.! S.S ± S.S 
Coagubtion time (min)' 21.1 ±22.9 14.2 ± 6 •• 
Maximum amplitude (mm) '5.9 ± 12.8 49.S ± 5.7* 
Clot formation rate (0) '7.6 ± 19 .• 44.S ±n.6 
Whole blood clot lysis 
index (%) 28.5 ±29.5 94.S ± 7.4* 
Whole blood clot lysis time 
(min) 75.7 ±S4.6 >IS0t 
Prothrombin time (5) 16.0 ± 1.9 16.S ± 1.7 
Activated partial 
thromboplastin time (.) 62.5 ±2S.1 57.6 ± 15,0 
Thrombin time (s) 50.4 ± 10.9 gO.1 ± 10.9 
Platelet count (IOOO/mm,) 1S2.6 ±80.5 llS.1 ±S6.5 
Fibrinogen (mg'.l) 12S.2 ±48.1 124.2 ±3S.9 
Factor II (U/mJ) 0.46± 0.11 0.45± 0.11 
Factor V (U/mJ) 0.22± O.OS 0.20± 0.06 
Factor VII (u/m!) O.gS ± 0.10 0.g4± 0.09 
Factor VllI (u/mJ) 0.9S± 0.67 0.91 ± 0.62 
Values are mean ± SD. 
* P < 0.05 compared with themrresponding values before EACA. 
t Whole blood dot lysis time was greater than ISO min in aD oc-
casions. 
TABLE 5. Frequency Distribution of Whole Blood Clot Lysis Time. 
Euglobulin Lysis Time. Fibrin Degradation Products. 
and Fibrin Monomers in 20 Patients Who Received 
... aminocaproic Acid (EACA. I g) 
Number of Patienu 
Bd'o", 10 Min Aller 
Variable MCA MCA 
Whole blood clot lysis time 
0-60 min 9 0 
61-120 min 11 0 
121-1S0 min 0 0 
>180 min 0 20 
Euglobulin lysis time 
0-60 min 14 10 
61-120 min 4 S 
>120 min 2 2 
Fibrin degradation products 
o Jlg/ml 10 8 
10-40 Jlg/ml 7 8 
>40 Jlg/ml ~ 4 
Fibrin monomers 
0 5 5 
+ 10 S 
++ 5 6 
+++ 0 1 
Whole blood clot lysis time and euglobulin lysis time increased 10 
min after EACA administration. 
Discussion 
Fibrinolysis is well recognized in patients with acute 
and chronic liver disease. Active fibrinolysis, manifest as 
weak blood dots or generalized oozing that necessitates 
continuous blood transfusion, is the most striking feature 
of the coagulation system during liver transplantation. 
Cirrhotic patients are prone to fibrinolysis even after rel-
atively benign stimuli, IS and show an exaggerated fibri-
nolytic response to vasoactive substances. Delayed hepatic 
clearance of circulating plasminogen activators, defective 
synthesis or decreased levels of naturally occurring inhib-
itors, and activation of p~tein C have been postulated as 
responsible for the fibrinolysis in patients with liver cir-
rhosis.14-17ll However, it is controversial whether the fi-
brinolytic activity in patients with liver disease is primary 
or secondary to disseminated intravascular coagulation, 
mainly because of difficulties in differentiation by labo-
ratory tests. II 
In our experience. fibrinolysis occurring during liver 
transplantation has appeared to be primary in origin. 
Prolonged PT and aPTT, thrombocytopenia, hypofibri-
nogenemia, decrease in coagulation factors, positive fibrin 
degradation products, positive soluble fibrin monomers, 
and decrease in antithrombin III are the typical laboratory 
, Comp PC, Esmon CT: Initiation of clot lysis in plasma by activated 
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findings in patients with disseminated intravascular co-
agulation. 19 But it is not unusual to observe similar 
changes before and during liver transplantation without 
signs of fibrinolysis, as evidenced by similar levels of co-
agulation factors in patients with and without fibrinolysis. 
This poor coagulation state is due mainly to poor hepa-
tocellular synthetic function and intraoperative dilution. 
During liver transplantation, only minimal quantities of 
circulating fibrin monomers and fibrin degradation prod-
ucts have been detected during fibrinolysis,20 although 
high levels of fibrin monomers and fibrin degradation 
products are frequently seen in disseminated intravascular 
coagulation. In this study. FDP level was relatively low 
during the fibrinolytic stage, and use of EACA did not 
decrease FDP level. Levels of fibrin degradation products 
can be high during liver transplantation, but this usually 
occurs toward the end of surgery. when fibrinolysis is no 
longer seen. possibly from reabsorption of extravascular 
blood and fibrinous exudate or delayed hepatic reticu-
loendothelial clearance of fibrin degradation products.21 
In secondary fibrinolysis. hypercoagulation precedes hy-
pocoagulation. In our experience, a normal or hyperco-
agulable state has been very rare in patients receiving 
liver transplants. having occurred only in a few patients 
with neoplasms or Budd-Chiari syndrome. Furthermore. 
the hypocoagulable state commonly seen in the preop-
erative period in our patients responds readily to replace-
ment therapy. 
Most important. Lewis et al. observed a disproportional 
decrease in factors V and VIII:C during the anhepatic 
stage and upon reperfusion of the graft liver, and sug-
gested that these factors might be destroyed selectively 
by circulating plasmin in the process of active fibrino-
lysis.!O They found that the plasminogen level decreased 
moderately during the anhepatic stage, while the anti-
plasmin level decreased precipitously during the anhepatic 
stage and after reperfusion. Since fibrinolysis occurs when 
the balance between activators ~d inhibitors is impaired; 
the occurrence of primary fibrinolysis during liver trans-
plantation is not surprising. 
In the present study, although fibrinolysis was most 
dramatic upon reperfusion of the graft liver, it was seen 
during the preanhepatic and anhepatic stages as well. Fi-
brinolysis during the preanhepatic and anhepatic stages 
may be caused by decreased clearance of circulating ac-
tivated plasminogen, release of tissue and vascular plas-
minogen activators, and decreased synthesis of inhibitors: 
However. the "explosive" fibrinolysis seen early in the 
postanhepatic stage may be caused by substances origi-
nating from the donor liver. Because it occurs within 5 
min after reperfusion of the graft liver, sudden quanti-
tative changes in coagulation facton and fibrinolytic pro-
teins in the recipients are unlikely to have occurred. Al-
though the graft is preserved hypothermically in a solution 
with intracellular composition, changes in cellular mem-
brane permeability are expected to occur. The release 
from the donor liver of substances activating plasminogen 
or suppressing inhibitors of fibrinolysis may cause explo-
sive fibrinolysis after reperfusion. 
Although fibrinolysis occurs frequently during hepatic 
surgery. it has been treated only sporadically. Grossi et 
al. used EACA in patients who developed marked fibri-
nolysis and severe oozing during portacaval shunt pro-
cedures, and it appeared to prevent fibrinolysis and 
bleeding.22 In a study of animals receiving liver grafts, 
EACA did not seem to prevent fibrinolysis. 25 Flute et al. 
reported a possible beneficial role of EACA in liver trans-
plantation patients.' Pharmacologic anti fibrinolytic ther-
apy was instituted by von Kaulla et al., who reported giving 
EACA (1 g/h) to three patients during liver transplan-
tation and several days postoperatively.6 EACA appeared 
to stop fibrinolysis in all three patients. but one died in-
traoperatively with uncontrollable bleeding. Deep venous 
thrombosis developed in one patient and pulmonary em-
boli in the other. After observing a high incidence of hy-
percoagulable state and pulmonary emboli in their pa-
tients with and without EACA therapy, von Kaulla et al. 
suggested that the fibrinolysis during liver transplantation 
was a self-limiting process caused by organ systems other 
than the liver. and that pharmacologic manipulation of 
the coagulation system during liver transplantation was 
not necessary and might be harmful. However, thrombosis 
in major vessels is not uncommon in patients with liver 
disease.24 and all their adult patients had neoplasms, with 
which a hypercoagulable state is known to be associated. 
If the thrombotic complications were associated with an-
tifibrinolytic therapy, they could have been caused by a 
residual effect of relatively large doses of EA CA (100 mg/ 
kg). which may have interfered with the delicate balance 
between coagulation and fibrinolysis in the postoperative 
period. 
The controvenysurrouilding Clinical use of EACA 
stems from several difficulties in anti fibrinolytic therapy. 
First. the indications for anti fibrinolytic therapy have been 
unclear. In surgical patients, EACA has been used in cases 
of severe generalized oozing with short EL T and bleeding 
from un traumatized sites. However, generalized bleeding 
is not necessarily caused by fibrinolysis, and EL T reflects 
only the activity of plasminogen. Although EL T is known 
to correlate with whole blood clot lysis time, a poor cor-
relation was found in this study. EL T measures only the 
. activity of plasminogen, not other substances affecting the 
fibrinolytic system, such as plasmin and inhibitors. A bal-
ance between plasminogen activators and its inhibitors 
may be a better indicator of fibrinolysis.25 
Second, monitoring of fibrinolysis has been inadequate. 
In the present study, TEG was used to monitor fibrino-
lysis. TEG demonstrale$ the net balance of the fibrinolytic 
A~ 
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system, including activators and inhibitors, which more 
accurately reflects in vivo conditions. TEG has been shown 
to be a reliable technique and to correlate with the co-
agulation profile.26 Its selective sensitivity and reliability 
as a test for fibrinolysis have been demonstrated by von 
Kaulla in a study of serial changes in whole blood clot 
lysis time after administration of pyrogenic lipopolysac-
charide in humans.27 Recently, Summaria et al. showed a 
progressive decrease in whole blood clot lysis time when 
incremental doses of the plasminogen activator, p-chain-
streptokinase, were added to whole blooci,28 Streptokinase 
that was given to patients with thrombotic conditions 
showed similar changes in whole blood clot lysis time. 
Third, EACA therapy may lead to thrombotic com-
plications. Although rapid fibrinolysis, ranging from no 
clotting at all to a rapid total blood clot lysis that accom-
panied massive intraoperative intragastric bleeding, was 
observed frequently, and the effectiveness of antifibri-
nol}tic therapy was demonstrated repeatedly in vitro, we 
did not use EACA in patients in our ~rly experience 
because we feared possible thrombotic complications,29 
such as thrombosis of the portal vein, inferior vena cava, 
or hepatic artery or pulmonary emboli. Microemboli in 
the renal glomerular capillaries may impair complex 
postoperative renal function. In this study, hemorrhagic 
or thrombotic complications developed intra- or postop-
eratively in four patients. but they had not received 
EACA. Two of these patients had massive pulmonary em-
boli intraoperatively, in the beginning of the anhepatic 
stage using vena-veno bypass. Their pre- and intraoper-
ative coagulation profiles and TEG patterns were poor, 
and it appears that migration of preexisting thrombi in 
the portal vein or deep venous system occurred. Sub-
arachnoid hemorrhage was diagnosed postoperatively in 
one patient, but the intracranial pathology appeared to 
have been present preoperatively. One patient had de-
veloped a postoperative hepatic arterial thrombosis, which 
is not uncommon after major tsculaiDs~rgery~-D-"- ---
Fourth. the optimal clinical dose ofEACA has not been 
identified. McNicol et al. recommended oral or intrave-
nous administration of 1 g EACA every hour after a 
priming dose of 4-5 g to achieve an EACA plasma level 
of 13 mg%.!O However. this dosage is based on complete 
inhibition of fibrinolysis in viJro. and the individual clinical 
situation should dictate its own dose schedule. The fibri-
nolytic process during liver transplantation was severe, 
although transient (less than 8 h). and. when stopped in 
the initial stage with a minimal dose ofEACA, progressive 
coagulopathy was prevented without untoward effect. 
EACA is almost completely eliminated in urine within 6 
h, and one would expect the residual effect of 1 g ofEACA ' 
to be negligible in the latter part of surgery and the post-
operative period. In the present study, the dose ofEACA 
used for in vitro evaluation of fibrinolysis was fivefold 
larger than the clinical dose. McNicol et al. showed that 
a larger dose of EACA (130 mg%) was needed to inhibit 
plasminogen activity in vitro, so while Lerner et at. found 
that a dose four times smaller than the in vitro dose was 
sufficient to arrest fibrinolysis during open-heart sur-
gery."'''' In this study, the effectiveness of EACA was tested 
in vitro. EACA accelerates coagulation by shifting the 
equilibrium away from fibrinolysis. But, in healthy subjects 
with minimal fibrinolysis, the changes in reaction time 
and coagulation time are minimal, and changes in fibri-
nolysis time and whole blood clot lysis index are not seen 
(Kang YG, unpublished data). EACA was used only when 
certain criteria were met: severe fibrinolysis was seen on 
TEG. EACA halted fibrinolysis in vitro, and generalized 
oozing occurred from a previously dry surgical field. 
Therefore, the indications for EACA use were not only 
its effectiveness in vitro, but also the demonstration of se-
vere fibrinolysis by both laboratory techniques and clinical 
signs. 
This study was not designed to evaluate the clinical 
effectiveness of EACA in a double-blind fashion, because 
mild fibrinolysis may not require treatment and with-
holding beneficial treatment from a patient with severe 
fibrinolysis is not justified. Evaluating the clinical effec-
tiveness of anti fibrinolytic therapy in terms of transfusion 
requirements. particularly during liver transplantation, is 
difficult. The transfusion requirement is influenced by 
many factors: preoperative status of the coagulation sys-
tem including its vascular phase, difficulties in surgery, 
technical skill of the surgeons, adequacy of blood replace-
ment and pharmacologic therapy. and quality of the donor 
organ. Therefore, blood loss was not compared between 
patients who did and who did not receive EACA. 
The present study demonstrated the safety of EACA 
therapy in a large series of patients undergoing liver 
transplantation. First, thrombelastographic monitoring of 
the coagulation system, which monitors the balance of 
fibrinolytic activity arid igie"Dactfviiyof1n1iibito~T dearly 
identified any imbalance in the fibrinolytic system. Second, 
the drug was administered only when fibrinolytic activity 
was demonstrated by TEG, EACA was proven effective 
by TEG in EACA-treated blood, and generalized oozing 
from a previously dry surgical field occurred. Third, a 
very small single dose (1 g) was used in this study. and 
was clinically effective in all cases. We do not know 
whether an even smaller dose might be equally effective 
during liver transplantation, or whether the small dose 
we used is suitable for other patients requiring antifibri-
nolytic therapy. Fourth. it is interesting that major vas-
cular thrombotic complications occurred only in patients 
•• Lerner RC. Reed CE, NelsonJC. Pooley R, Moggio R. Somberg 
E, Praeger P: Rapid monitoring and treatment of fibrinolysis associated 










773 KANG ET .iL Ann'hcsK>ior V 66. So 6. Jun 1987 
not given EACA. Although blood urea nitrogen and 
serum creatinine level are crude assessments of renal 
function, and hepatorenal syndrome and cydosporine 
nephrotoxicity could have affected postoperative renal 
function, the values were similar in treated and untreated 
patients. Subnormal levels of coagulation factors and 
platelets are common in patients receiving liver trans-
plants, and a transient arrest of fibrinolysis is unlikely to 
cause thrombosis. 
In summary, most patients undergoing liver transplan-
tation demonstrated active fibrinolysis, evidenced by TEG 
monitoring and shortened ELT. EACA (1 g) was given 
to patients who showed active fibrinolysis and generalized 
oozing when the drug was proven effective by TEG in 
EACA-treated blood in vitro. It effectively treated fibri-
nolysis in all cases, and complications associated with its 
use were not observed. 
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